Abstract

The Global CEO Initiative on Alzheimer’s Disease is a public-private partnership that aims to stop Alzheimer’s disease (AD) and dementia. The consortium brings together international public authorities with the private sector to serve as the leading business voice on AD.

Mission

The CEO Initiative on AD aims to identify and pursue research, therapy development, financing, and public awareness projects of the highest priority that, when achieved, can transform the global fight to stop AD.

The CEO Initiative aims to spur innovation and facilitate opportunities to improve the care of those affected by AD; reduce the time, cost, and risk of drug development to improve the productivity of research and development investments; accelerate a means of prevention and treatment of AD,
including improving the ability to identify and diagnose the disease; spur new models for care, care preparation, and care delivery; and re-shape the environment in which society addresses AD patients and caregivers.

Structure & Governance

Several working groups support the CEO Initiative. The Research Working Group, co-led by Sanofi SA and the New York Academy of Sciences, develops and advances a prioritized comprehensive research agenda, one that is informed by all parties including government, academia, and industry. A major undertaking is a planned June 2013 research summit to be hosted by the Academy and designed to continue the actions begun in 2012 by the National Institute on Aging Alzheimer’s Disease Summit. The 2013 research summit will bring together a broad set of AD stakeholders, including academia, industry, patient advocates, and governmental leaders, to produce an agreed upon set of research priorities that will inform all AD research efforts, including resource allocation, moving forward.

The Pipeline Compression Working Group, co-led by Janssen Pharmaceuticals, a division of Johnson & Johnson, and the Critical Path Institute’s Coalition Against Major Diseases (CAMD), focuses on ways to reduce the time, cost, and risk in developing therapies and treatments, particularly those for AD and dementia. The scope of issues before the working group is wide-ranging, including establishing common data standards to facilitate scientific collaborations and accelerate U.S. Food and Drug Administration (FDA) review of drug applications; achieving breakthroughs in developing and qualifying AD biomarkers; developing robust patient registries to accelerate clinical trial recruitment; and expanding access to clinical trial data to prevent duplicative research, reduce unnecessary costs and risks, and accelerate the pace of development of therapies and treatments.

The Clinical Trial Enrollment Working Group is closely related to the Pipeline Compression Working Group and is led by Banner Health and the Banner Alzheimer’s Institute, with the objective of developing a robust and well-defined patient registry to expedite the often slow and costly process of recruiting and enrolling patients in clinical trials.

The Awareness Raising & Stigma Reduction Working Group is co-led by Eli Lilly and Company, Bank of America, and the National Council on Aging to bolster existing government and nongovernmental awareness-raising and stigma-reduction efforts to encourage those showing symptoms of cognitive or other brain impairment — and their caregivers — to seek medical advice and a diagnosis as well as other
supportive services. By keying into the “value of knowing,” this effort ultimately aims to improve the quality of life for all those affected by AD and other dementias through ensuring access to quality care and services.

Homepage  http://www.ceoalzheimersinitiative.org/

Sponsors & Partners

AC Immune
Bank of America
Banner Health
GE
Home Instead Senior Care
Janssen
Lilly
MERCK
Nestle Health Science
Pfizer, Inc
Sanofi
Takeda Pharmaceuticals

Updated: 04/18/2016